Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

1.

Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.

Sato A, Fukuda S.

J Hum Hypertens. 2010 Jun;24(6):387-94. doi: 10.1038/jhh.2009.81. Epub 2009 Oct 29.

PMID:
19865106
[PubMed - indexed for MEDLINE]
2.

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.

Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH.

Circulation. 2003 Oct 14;108(15):1831-8. Epub 2003 Sep 29.

PMID:
14517164
[PubMed - indexed for MEDLINE]
Free Article
3.

Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.

Burgess ED, Lacourcière Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S, Roniker B, Maurath C.

Clin Ther. 2003 Sep;25(9):2388-404.

PMID:
14604739
[PubMed - indexed for MEDLINE]
4.

Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.

Ando K, Ohtsu H, Arakawa Y, Kubota K, Yamaguchi T, Nagase M, Yamada A, Fujita T; Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Study Investigators.

Hypertens Res. 2010 Jun;33(6):616-21. doi: 10.1038/hr.2010.46. Epub 2010 Apr 9.

PMID:
20379190
[PubMed - indexed for MEDLINE]
5.

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.

Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E.

J Am Coll Cardiol. 2003 Apr 2;41(7):1148-55.

PMID:
12679215
[PubMed - indexed for MEDLINE]
Free Article
6.

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.

Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K.

Hypertension. 2002 Aug;40(2):117-23.

PMID:
12154100
[PubMed - indexed for MEDLINE]
Free Article
7.

Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.

White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W.

Am J Cardiol. 2003 Jul 1;92(1):38-42.

PMID:
12842242
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.

Saruta T, Kageyama S, Ogihara T, Hiwada K, Ogawa M, Tawara K, Gatlin M, Garthwaite S, Bittman R, Patrick J.

J Clin Hypertens (Greenwich). 2004 Apr;6(4):175-83; quiz 184-5.

PMID:
15073471
[PubMed - indexed for MEDLINE]
9.

Clinical implications of aldosterone blockade.

Weber MA.

Am Heart J. 2002 Nov;144(5 Suppl):S12-8. Review.

PMID:
12422136
[PubMed - indexed for MEDLINE]
10.

Effects of eplerenone versus losartan in patients with low-renin hypertension.

Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B, Patrick JL, Krause SL.

Am Heart J. 2005 Sep;150(3):426-33.

PMID:
16169319
[PubMed - indexed for MEDLINE]
11.

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.

Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51. Epub 2006 Jul 19.

PMID:
17699311
[PubMed - indexed for MEDLINE]
Free Article
12.

Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.

Sato A, Fukuda S.

Hypertens Res. 2013 Oct;36(10):879-84. doi: 10.1038/hr.2013.74. Epub 2013 Jul 18.

PMID:
23864056
[PubMed - indexed for MEDLINE]
13.

Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?

Prisant LM, Krum H, Roniker B, Krause SL, Fakouhi K, He W.

J Clin Pharmacol. 2003 Nov;43(11):1203-10.

PMID:
14551174
[PubMed - indexed for MEDLINE]
14.

Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.

Hollenberg NK, Williams GH, Anderson R, Akhras KS, Bittman RM, Krause SL.

Arch Intern Med. 2003 Jul 14;163(13):1543-8.

PMID:
12860576
[PubMed - indexed for MEDLINE]
16.

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.

White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA.

Hypertension. 2003 May;41(5):1021-6. Epub 2003 Apr 7. Erratum in: Hypertension. 2003 Dec;42(6):e20.

PMID:
12682082
[PubMed - indexed for MEDLINE]
Free Article
17.

The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.

Davis KL, Nappi JM.

Clin Ther. 2003 Nov;25(11):2647-68. Review.

PMID:
14693297
[PubMed - indexed for MEDLINE]
18.

Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study.

Shavit L, Neykin D, Lifschitz M, Slotki I.

Clin Nephrol. 2011 Nov;76(5):388-95.

PMID:
22000559
[PubMed - indexed for MEDLINE]
19.

Eplerenone: a selective aldosterone blocker.

Stier CT Jr.

Cardiovasc Drug Rev. 2003 Fall;21(3):169-84. Review.

PMID:
12931252
[PubMed - indexed for MEDLINE]
20.

Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.

Moore TD, Nawarskas JJ, Anderson JR.

Heart Dis. 2003 Sep-Oct;5(5):354-63. Review.

PMID:
14503934
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk